Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-06342674
- Development stage
- Discontinued
- Lead developer
- Pfizer
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
PF-06342674 is a monoclonal antibody developed by Pfizer that targets the alpha chain of the interleukin-7 receptor (IL-7Ra), also known as CD127. By binding to CD127, the drug acts as an antagonist to inhibit IL-7-mediated signaling, which is essential for the survival, proliferation, and differentiation of T cells. This mechanism is intended to suppress the activity of pathogenic effector and memory T cells that drive autoimmune responses. PF-06342674 was primarily investigated for the treatment of type 1 diabetes mellitus and multiple sclerosis. However, clinical development for these indications was terminated by Pfizer for strategic business reasons rather than safety concerns.
- Other names
- Anti-CD127 mAbAnti-CD-127 mAbAnti-CD 127 mAbAnti-IL-7Ra mAbAnti-IL7Ra mAbAnti-IL 7Ra mAb
02
Targets
IL7R (Interleukin-7 Receptor)
Beyond the preview
Go deeper on PF-06342674.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-06342674.